Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the target of a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 610 shares, a decline of 97.6% from the January 29th total of 24,900 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average daily volume of 7,063 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 7,063 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.4% of the company’s shares are sold short.

Institutional Investors Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC boosted its position in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,891 shares of the company’s stock after purchasing an additional 1,215 shares during the period. Jane Street Group LLC owned approximately 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent reporting period.

Amplify Weight Loss Drug & Treatment ETF Price Performance

THNR stock traded down $0.38 during midday trading on Thursday, reaching $25.62. 1,485 shares of the company’s stock traded hands, compared to its average volume of 3,526. Amplify Weight Loss Drug & Treatment ETF has a fifty-two week low of $18.56 and a fifty-two week high of $27.28. The business has a 50-day moving average price of $26.03 and a two-hundred day moving average price of $24.64. The company has a market capitalization of $3.84 million, a P/E ratio of 24.31 and a beta of 0.61.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The business also recently declared an annual dividend, which was paid on Wednesday, December 31st. Investors of record on Tuesday, December 30th were issued a $0.4132 dividend. This represents a yield of 162.0%. The ex-dividend date was Tuesday, December 30th.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.